Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
NEWARK, CA / ACCESSWIRE / September 3, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY.
2024年9月3日,智能治療公司(納斯達克代碼:PTGX)(以下簡稱「智能治療」或「公司」)宣佈,總裁兼首席執行官Dinesh V. Patel博士將在紐約的H.C. Wainwright第26屆全球投資博覽會上參加座談會和一對一會議。
H.C. Wainwright 26th Annual Global Investment Conference - September 9-11, 2024
H.C. Wainwright第26屆全球投資會議-2024年9月9日至11日
Format: Fireside Chat
Day/Time: Tuesday, September 10 at 1:30 P.M. ET
Webcast:
形式:爐邊聊天
日期/時間:9月10日星期二 下午1:30 ET
網絡直播:
If you are interested in meeting with the Protagonist team during the conference, please reach out to your H.C. Wainwright representative.
如果您有興趣在會議期間與智能治療團隊會面,請聯繫您的H.C. Wainwright代表。
About Protagonist
關於主角
Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced Phase 3 stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist and Johnson & Johnson (JNJ) scientists jointly discovered JNJ-2113 as part of Protagonist's Interleukin-23 receptor (IL-23R) antagonist collaboration with JNJ and followed it through IND-enabling pre-clinical and Phase 1 studies, with JNJ assuming responsibility for further clinical development. JNJ-2113 is currently being pursued in five Phase 3 studies in psoriasis, and a Phase 2b study in ulcerative colitis. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development program for polycythemia vera (PV). The randomized portion of the Phase 2 REVIVE study has been successfully completed, and results were published in The New England Journal of Medicine in February 2024. The open-label extension (OLE) component of REVIVE has also been completed and is followed by an additional 2-year long-term extension (LTE) THRIVE study. Enrollment has been completed in the global Phase 3 VERIFY study of rusfertide in polycythemia vera. Rusfertide is being co-developed and co-commercialized with Takeda pursuant to a worldwide collaboration and license agreement with Takeda announced in January 2024.
Protagonist Therapeutics是一家生物製藥公司,擁有基於肽的新化學實體(NCE)rusfertide和JNJ-2113(原名PN-235),處於臨床開發的先進第3階段,這兩種藥物都來自公司的專有技術平台。Protagonist和強生(JNJ)的科學家在合作中共同發現了JNJ-2113,隨後進行了IND前臨床和第1期研究,JNJ則負責進一步的臨床開發。JNJ-2113目前正在進行五項銀屑病第3期研究和一項潰瘍性結腸炎第20億階段的研究。 Rusfertide作爲一種天然荷爾蒙hepcidin的類似物,是該公司的股票候選藥物,目前正在進行全球第3期開發計劃,用於紅細胞增多症。第2期REVIVE研究的隨機部分已經成功完成,並於2024年2月發表於《新英格蘭醫學雜誌》中。REVIVE的開放標籤延伸(OLE)組分還已經完成,並隨後是另外的2年長期延伸(LTE)THRIVE研究。rusfertide的全球第3期VERIFY試驗的招募已經完成。rusfertide正在與武田共同開發和銷售,根據於2024年1月宣佈的全球合作和許可協議。
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at .
有關Protagonist,其管道藥物候選和臨床研究的更多信息可在該公司的網站上找到。
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
投資者關係聯繫人
Corey Davis,博士。
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Media Contact
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
virginiaamann@ententeinc.com
媒體聯繫人
Virginia Amann,創始人/首席執行官
ENTENTE公司網絡
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics, Inc.
消息來源:Protagonist Therapeutics,Inc。
譯文內容由第三人軟體翻譯。